Business Wire

CA-BIOCYTOGEN

31.7.2024 12:01:30 CEST | Business Wire | Press release

Share
Biocytogen Announces Option and License Agreement with IDEAYA Biosciences for Potential First-in-Class B7H3/PTK7 Topo-I-Payload Bispecific ADC Program

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, HKEX: 02315), a global biotech company focusing on the discovery of novel antibody/ADC therapeutics, announced that it has entered into an option and license agreement for a potential first-in-class B7H3/PTK7 BsADC program with IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics.

“We are thrilled to announce our collaboration with IDEAYA to explore the promising combination of our potential first-in-class ADC and IDEAYA’s DDR small molecules,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “This partnership leverages our cutting-edge RenLite® platform and proprietary linker-payload technology to enhance the precision and potency of ADCs. IDEAYA's strong determination and rich experience in drug development make us confident that this therapy could be rapidly advanced to benefit patients.”

“The potential first-in-class B7H3/PTK7 topo-I-payload BsADC program has the potential to be developed as a monotherapy agent in multiple solid tumor types, and advances IDEAYA’s broader corporate strategy to enable wholly-owned first-in-class rational combinations at the intersection of ADCs and small molecule DDR-based therapies to deliver greater benefit for patients,” said Yujiro S. Hata, President and Chief Executive Officer, IDEAYA Biosciences.

The agreement grants IDEAYA an option for an exclusive worldwide license from Biocytogen for a potential first-in-class B7H3/PTK7 topo-I-payload BsADC program. B7H3/PTK7 has been found to be co-expressed in multiple solid tumor types, including double-digit percent prevalence in lung, colorectal, and head and neck cancers, among others.

Under the terms of the agreement, Biocytogen will receive an upfront fee and upon an option exercise by IDEAYA, be entitled to receive an option exercise fee, development and regulatory milestones and commercial milestone payments, as well as single-digit royalties on net sales. Total potential upfront, option exercise and milestone payments equal an aggregate of $406.5 million, including development and regulatory milestones of $100.0 million.

Based on preclinical data, the potential first-in-class B7H3/PTK7 topoisomerase-I-inhibitor-payload BsADC program has the potential to be developed as a monotherapy agent and used in combination with multiple programs in IDEAYA’s pipeline targeting DDR-based therapies, including PARG inhibitor IDE161. A development candidate nomination for the B7H3/PTK7 topoisomerase-I-inhibitor payload BsADC program is targeted for the second half of 2024.

About Biocytogen
Biocytogen (HKEX: 02315) is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Founded on gene editing technology, Biocytogen leverages genetically engineered proprietary RenMice® (RenMabTM/ RenLite®/ RenNano®/ RenTCR-mimicTM ) platforms for fully human monoclonal/bispecific/multispecific antibody discovery, bispecific antibody-drug conjugate discovery, nanobody discovery and TCR-mimic antibody discovery, and has established a sub-brand, RenBiologicsTM, to explore global partnerships for an off-the-shelf library of >400,000 fully human antibody sequences against approximately 1000 targets for worldwide collaboration. As of December 31, 2023, 103 therapeutic antibody and multiple clinical asset co-development/out-licensing/transfer agreements and 47 target-nominated RenMice® licensing projects have been established around the globe, including several partnerships with multinational pharmaceutical companies (MNCs). Biocytogen pioneered the generation of drug target knock-in humanized models for preclinical research, and currently provides a few thousand off-the-shelf animal and cell models under the company’s sub-brand, BioMiceTM, along with preclinical pharmacology and gene-editing services for clients worldwide. Headquartered in Beijing, Biocytogen has branches in China (Haimen Jiangsu, Shanghai), USA (Boston, San Francisco), and Germany (Heidelberg). For more information, please visit http://en.biocytogen.com.cn.

About IDEAYA Biosciences
IDEAYA is a precision medicine oncology company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. IDEAYA’s approach integrates capabilities in identifying and validating translational biomarkers with drug discovery to select patient populations most likely to benefit from its targeted therapies. IDEAYA is applying its research and drug discovery capabilities to synthetic lethality – which represents an emerging class of precision medicine targets.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240731592628/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Helical Fusion Awarded Up to JPY 19.2 Billion in Japanese Government Funding to Accelerate Commercial Fusion Power18.11.2026 13:36:00 CET | Press release

Bringing together Japan’s fusion research and manufacturing expertise to advance commercial fusion Helical Fusion Co., Ltd., a fusion energy company developing commercially viable power plants based on Helical Stellarator technology, has been formally selected for a major Japanese government grant program administered by the Ministry of Economy, Trade and Industry (METI). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261118128278/en/ The maximum government subsidy is approximately JPY 19.2 billion (USD 126 million). The grant-supported project is scheduled to run through February 2029. Through the Helix Program, Helical Fusion leads overall plant design and systems integration, drawing on research from Japan’s national research institutions and the engineering and manufacturing expertise of approximately 40 companies in Japan. The program aims to turn Japan’s scientific and industrial strengths into practical fusion power.

Grand Prix ACF AutoTech 2027: Applications Open for the 10th Edition18.11.2026 13:00:00 CET | Press release

Since 2018, the competition’s 52 finalists have raised more than €700 million The Automobile Club de France (ACF) and ESSEC Alumni are launching the 10th edition of the Grand Prix ACF AutoTech, the leading competition for automotive and mobility startups. French and international startups can apply until November 27, 2026 at 11:59 p.m. (CET) at www.grandprixacfautotech.com. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261118772168/en/ Jury members and former finalist startups for the launch of 10th Edition of Grand Prix ACF AutoTech (c) Quentin Vaquez Since 2018, the competition has selected 52 finalists, including Chargemap, Hiflow, ChargeGuru and Geolith, who have together raised more than €700 million. Only 6 have failed: a survival rate of nearly 90%. The 2026 edition rewarded Altrove (Grand Prix ACF), Bloomineral (ACF Pioneer Prize and GreenTech Mention) and IoT.bzh (Industrialization Prize). “Ten editions is an achie

New TOURISE Report Reveals How Traveler Expectations Are Changing the Rules for Global Tourism18.11.2026 13:00:00 CET | Press release

Report urges tourism leaders to focus on high-value trips, not just high-spending visitors, and measure benefits retained by local communities Nearly 150 million more households could afford international leisure travel by 2030, including almost 110 million in Asia Pacific 59% of surveyed AI users turn to AI for travel information, but only 12% of consumers in a separate survey trust it to make decisions independently 43% of travelers surveyed across 35 markets planned to avoid overcrowded destinations in 2026 Changing traveler priorities are reshaping global tourism, influencing where people go, how they spend and what they value most from their journeys. A new report released by TOURISE, The Future Traveller, explores these shifts and what they mean for the industry through 2030. Developed in collaboration with Euromonitor International, the report draws on consumer surveys and perspectives from industry leaders. The report finds that travel decisions are increasingly shaped by the p

Rockwell Automation Signs Definitive Agreement to Acquire AGILOX18.11.2026 13:00:00 CET | Press release

This acquisition accelerates our physical AI strategy and creates a comprehensive autonomous mobile robot portfolio Rockwell Automation, Inc. (NYSE: ROK), the world’s largest company dedicated to industrial automation and digital transformation, today announced it has signed a definitive agreement to acquire Austria-based AGILOX, a maker of high-end autonomous mobile robots (AMRs) that are driven by self-developed artificial intelligence and swarm networking technology. Together, AGILOX’s proven forklift AMR portfolio and OTTO by Rockwell Automation’s flatbed AMR platform will create a comprehensive autonomous material movement offering, elevating AGILOX from a best-in-class point solution to a cornerstone of a world-class comprehensive production logistics capability. The acquisition will combine OTTO's strong presence in North America with AGILOX's established footprint across Europe. AGILOX will gain access to Rockwell's deep customer relationships in strategic verticals like consum

Ant International Pioneers PayNow Deep-Linking for E-Commerce, Explores Government Services Use Case Under MAS’ PayNow Gen2 Initiative18.11.2026 12:40:00 CET | Press release

Ant International’s Antom is the first to implement PayNow deep-link for e-commerce, via Lazada, with ~9% uplift in payment success rate.2C2P by Antom is collaborating with the Government Technology Agency of Singapore (GovTech Singapore) to explore PayNow deep-linking capabilities through GovWallet.Ant International will further explore supporting PayNow Gen2, including through its global wallet gateway Alipay+ expanding SGQR+ interoperability, and introducing AI-powered digital services for consumers and merchants. Ant International is the first partner under the Monetary Authority of Singapore (MAS)’s PayNow Generation 2.0 launch to introduce live use cases for deep-linking for e-commerce and digital government services. The launch is enabled by Antom, its global merchant payment and digitisation services provider, and Antom’s Southeast Asia subsidiary, 2C2P by Antom. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/202611183

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye